Michelle Petri Reviews New Therapies for Lupus

Save

In this video, Michelle Petri, MD, director of the Hopkins Lupus Center at Johns Hopkins University, discusses recent successes and challenges in the treatment of systemic lupus erythematosus, with clinical trials results ranging from "wildly positive" to "completely negative."

My Take on New Ocular Screening Guidelines for Plaquenil

Save

A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).

First Degree Relatives and the Risk of Spondyloarthritis

Save

The risk of developing ankylosing spondylitis (AS) if you are HLA-B27+ and a first degree relative is often said to be 20%.

Long-Term Outcomes of Aromatase Inhibitor Arthralgias

Save

Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.

Those with Osteoporotic Fractures are Going Untreated

Save

The International Osteoporosis Foundation (IOF) reports that nearly 80% of those who have already suffered a broken bone due to osteoporosis remain unprotected against the risk of further disabling fractures.

The Arthritis Spectrum after Lyme Infection - Something New

Save

Symptoms attributed to chronic Lyme disease are the bane of a rheumatologist’s existence. We often see patients referred for a variety of nonspecific complaints that do not resolve after antibiotic therapy, including the so-called post-Lyme disease syndrome.

NSAIDs Pose a Dose-Related Risk for Heart Failure Hospitalizations

Save

BMJ has reported the results of a case-control study that analyzed the risk of hospitalization from heart failure associated with the use of NSAIDs amongst healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom).

Demyelinating Disease is a Rare Complication of TNF Inhibition.

Save

A recent review has shown that tumor necrosis factor-α inhibitors (TNFi) rarely cause MS-like disorders.

Anabolic Abaloparatide Looks Promising in Osteoporosis Fracture Prevention

Save

The osteoporsis therapeutics arena is starting to fill with new drugs and novel mechanisms of action.

CDC Reports 31 Million Older Americans Don't Get Adequate Exercise

Save

The Sept.16th issue of MMWR reports that many Americans over age 50 are not getting sufficient exercise, thereby increasing their risk for falls, fractures and comorbidities, if not premature death. (Citation source http://buff.ly/2cPAcq9)

New Shingles Vaccine Effective for up to Four Years

Save

In the current issue of the NEJM, a Herpes zoster subunit vaccine was reported to be highly effective in adults - specifically in 2 studies (ZOE50 and ZOE70) targeting adults over age 50 and over age 70 years. (Citation source: http://buff.ly/2cMng17)

Adalimumab Lowers Risk of Uveitis Flares in Visual I Study

Save

Rheumatologists may encounter patients with intermediate, posterior and pan-uveitis as part of certain rheumatic diseases such as Behcet’s, but more frequently may be called on to co-manage these patients with steroid sparing agents.

CPAP Use Fails to Prevent CV Events in Sleep Apnea Patients

Save

There are numerous health hazards associated with obstructive sleep apnea (OSA), including an increased risk of cardiovascular events.

RheumNow Week in Review – 2 September 2016

Save

Dr. Jack Cush reviews highlights from this week in RheumNow:

Flares Portend Damage in Rheumatoid Arthritis - Time for a New Strategy?

Save

Disease flares are common in rheumatoid arthritis (RA), often causing patients to seek additional care, if not medication.

The frequency of flares varies amongst studies in different populations.  But the consequence of flares has only recently been studied.

Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab

Save

Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.

Drug Use Compounds Risk - Before and After Fragility Fractures

Save

Is the occurrence of a fragility fracture a missed opportunity to reduce exposure to prescription drugs associated with fracture risk?

Risk of Sepsis or Death Lower with Biologics in Rheumatoid Arthritis

Save

Researchers from Germany have analyzed their large prospective rheumatoid arthritis (RA) registry to address whether being on biologic therapies leads to poorer outcomes - namely sepsis or death, following a serious infection (SIE).

RheumNow Week in Review – 19 August 2016

Save

Dr. Cush reviews the RheumNow.com highlights in rheumatology for the week ending 19 August 2016.

ARCTIC Study Shows No Benefit to Ultrasound Remission in RA

Save

The goal in rheumatoid arthritis (RA) treatment is remission. But what level or method of remission is best?